Apolipoproteina B e rischio cardiovascolare: la posizione del Working Group on Best Practices della Divisione Lipoproteine e Malattie Vascolari dell’American Association for Clinical Chemistry (AACC)

AUTHORS

John H. Contois¹, Joseph P. McConnell², Amar A. Sethi³, Gyorgy Csako³, Sridevi Devaraj⁴, Daniel M. Hoefner⁵, G. Russell Warnick⁶
¹Maine Standards Company, Windham, ME
²Mayo Clinic, Rochester, MN
³National Institutes of Health, Bethesda, MD
⁴UC Davis Medical Center, Sacramento, CA
⁵Marshfield Clinic, Marshfield, WI
⁶Berkeley HeartLab Inc, Alameda, CA
Traduzione a cura di Maria Stella Graziani

ABSTRACT

Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices

CASI CLINICI – Case Reports

Volume:

Published on-line:

DOI:

Apolipoproteina B e rischio cardiovascolare: la posizione del Working Group on Best Practices della Divisione Lipoproteine e Malattie Vascolari dell’American Association for Clinical Chemistry (AACC)

AUTHORS

ABSTRACT

Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices

REFERENCES